John Nagi Kheir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Nagi Kheir has a total of 276 co-authors. Here are the top co-authors by number of shared publications:
James A. DiNardo
Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA; Department of Anesthaesia, Harvard Medical School, Boston, Massachusetts, USA
12 shared publicationsBrian D. Polizzotti
Department of Cardiology, Boston Children’s Hospital, Boston, USA
8 shared publicationsLindsay M. Thomson
Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts
7 shared publicationsSarah J. van Den Bosch
Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts
6 shared publications- Brian D. Polizzotti
Translational Research Laboratory Department of Cardiology, Boston Children's Hospital Department of Pediatrics Harvard Medical School Boston MA 02115 USA
5 shared publications Francesca Sperotto
Department of Cardiology, Boston Children’s Hospital, Boston, Massachusetts
5 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 14 (1) , 138
Esophageal resonance Raman spectroscopy tracks mixed venous oxygenation in experimental shock and hypoxemia
Introduction: Mixed venous oxygen saturation (SvO 2 ) reflects the balance between systemic oxygen delivery and consumption and is widely used as an indicator of tissue oxygenation in critically ill patients. However, its measurement requires invasive venous access. We evaluated whether a customized probe applied to the esophageal mucosa could provide a continuous measurement of regional capillary hemoglobin oxygen saturation (S Es O 2 ) that tracks changes in mixed venous oxygen saturation for early detection of experimental shock with minimal invasiveness. Methods: A miniaturized 405 nm resonance Raman spectroscopy (RRS) probe was developed to quantify esophageal regional capillary hemoglobin saturation (S Es O 2 ) based on spectral decomposition of oxy- and deoxy-hemoglobin Raman peaks. Two rat models were investigated: progressive hemorrhage (n = 12) and graded hypoxia (n = 9). At each stage, SvO 2 , S Es O 2 , arterial oxygen saturation (SaO 2 ), and serum lactate were measured. Tracking ability and diagnostic accuracy compared to SvO 2 and transabdominal near-infrared spectroscopy (NIRS) were evaluated using linear mixed-effects models (animal random intercepts), (cluster-bootstrapped) receiver operating characteristic curve (ROC) analyses, and Pearson correlation. Results: In both models, baseline S Es O 2 was ~20% higher than SvO 2 , consistent with a regional capillary measurement distinct from mixed venous blood. In hemorrhage, LME showed S Es O 2 was positively associated with SvO 2 (β = 0.53, 95% CI 0.43–0.62; p < 0.0001) and inversely associated with lactate (β = −0.15, 95% CI −0.18 to −0.12; p < 0.0001). In ROC analysis, S Es O 2 discriminated SvO 2 < 40% with AUC 0.98 (95% CI 0.95–1.00). For transabdominal NIRS, the AUC was 0.82 (95% CI 0.70–0.95). During graded hypoxia, S Es O 2 was also positively associated with SvO 2 (β = 0.51, 95% CI 0.43–0.60; p < 0.0001) and inversely associated with lactate (β = −0.11, 95% CI −0.13 to −0.09; p < 0.0001). Discrimination of S Es O 2 for SvO 2 < 40% was AUC 0.92 (95% CI 0.82–1.00). Transabdominal NIRS demonstrated discrimination with high uncertainty (AUC 0.56, 95% CI 0.23–1.00). Conclusions: Esophageal RRS enables molecularly specific measurement of regional capillary hemoglobin oxygen saturation and thereby tracks SvO 2 across distinct experimental shock paradigms. These preclinical findings support further investigation of esophageal RRS as a potential minimally invasive monitoring approach for detection of systemic oxygen imbalance.
- 15 October 2026
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 14 (1) , 138
Open AccessEsophageal resonance Raman spectroscopy tracks mixed venous oxygenation in experimental shock and hypoxemia
Introduction: Mixed venous oxygen saturation (SvO 2 ) reflects the balance between systemic oxygen delivery and consumption and is widely used as an indicator of tissue oxygenation in critically ill patients. However, its measurement requires invasive venous access. We evaluated whether a customized probe applied to the esophageal mucosa could provide a continuous measurement of regional capillary hemoglobin oxygen saturation (S Es O 2 ) that tracks changes in mixed venous oxygen saturation for early detection of experimental shock with minimal invasiveness. Methods: A miniaturized 405 nm resonance Raman spectroscopy (RRS) probe was developed to quantify esophageal regional capillary hemoglobin saturation (S Es O 2 ) based on spectral decomposition of oxy- and deoxy-hemoglobin Raman peaks. Two rat models were investigated: progressive hemorrhage (n = 12) and graded hypoxia (n = 9). At each stage, SvO 2 , S Es O 2 , arterial oxygen saturation (SaO 2 ), and serum lactate were measured. Tracking ability and diagnostic accuracy compared to SvO 2 and transabdominal near-infrared spectroscopy (NIRS) were evaluated using linear mixed-effects models (animal random intercepts), (cluster-bootstrapped) receiver operating characteristic curve (ROC) analyses, and Pearson correlation. Results: In both models, baseline S Es O 2 was ~20% higher than SvO 2 , consistent with a regional capillary measurement distinct from mixed venous blood. In hemorrhage, LME showed S Es O 2 was positively associated with SvO 2 (β = 0.53, 95% CI 0.43–0.62; p < 0.0001) and inversely associated with lactate (β = −0.15, 95% CI −0.18 to −0.12; p < 0.0001). In ROC analysis, S Es O 2 discriminated SvO 2 < 40% with AUC 0.98 (95% CI 0.95–1.00). For transabdominal NIRS, the AUC was 0.82 (95% CI 0.70–0.95). During graded hypoxia, S Es O 2 was also positively associated with SvO 2 (β = 0.51, 95% CI 0.43–0.60; p < 0.0001) and inversely associated with lactate (β = −0.11, 95% CI −0.13 to −0.09; p < 0.0001). Discrimination of S Es O 2 for SvO 2 < 40% was AUC 0.92 (95% CI 0.82–1.00). Transabdominal NIRS demonstrated discrimination with high uncertainty (AUC 0.56, 95% CI 0.23–1.00). Conclusions: Esophageal RRS enables molecularly specific measurement of regional capillary hemoglobin oxygen saturation and thereby tracks SvO 2 across distinct experimental shock paradigms. These preclinical findings support further investigation of esophageal RRS as a potential minimally invasive monitoring approach for detection of systemic oxygen imbalance.
- 12 August 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-3
Physiologic signatures during extubation readiness trials in neonates >35 weeks’ postmenstrual age
- 12 August 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-3
Physiologic signatures during extubation readiness trials in neonates >35 weeks’ postmenstrual age
- 3 August 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (8) , e2629399
Adherence to Sedative Weaning Opportunities and Length of Stay for Critically Ill Children
Importance: Prolonged sedative exposure in pediatric intensive care units (ICUs) is associated with adverse outcomes including delirium, withdrawal, and neurodevelopmental impairment. Clinical guidelines recommend timely weaning, but adherence to weaning opportunities and its association with clinical outcomes is unknown. Objectives: To evaluate adherence to sedative weaning opportunities and examine the association between weaning adherence and clinical outcomes among pediatric ICU patients. Design, Setting, and Participants: This multicenter cohort study included ICU patients at 4 pediatric academic medical centers admitted between January 1, 2011, and December 31, 2024, with greater than 48 hours of cumulative sedative infusion exposure. Data extraction and analyses were performed between February and November 2025. Neonatal ICU stays were excluded. Exposure: Weaning adherence, defined as the percentage of identified opportunities to wean from sedation that resulted in weaning actions (dose decreases or discontinuations), calculated at the ICU encounter level. An opportunity was defined as 0 or 1 as-needed doses of any sedative in a 12-hour period. Main Outcomes and Measures: The primary outcomes were ICU and hospital length of stay. Secondary outcomes included infusion duration and cumulative sedative dose of each drug class. Multivariable linear regression models adjusted for center, age, and sex examined associations between weaning adherence and outcomes. Results: The cohort included 15 747 ICU encounters from 12 737 patients (median age, 1.1 years [IQR, 0.2-6.5 years]; 56% of encounters among male patients). Median ICU length of stay was 13 days (IQR, 7-25 days) and median hospital length of stay was 26 days (IQR, 14-55 days). Among a median of 30 (IQR, 13-68) opportunities to wean per ICU encounter, overall adherence to weaning opportunities was 28% (IQR, 14%-49%), while missed weaning opportunities were common (median, 72%; IQR 51%-86%). Higher weaning adherence was associated with shorter median ICU length of stay (–2.3 days [IQR, –2.4 to –2.2 days] per 10% increase; P < .001) and shorter median total hospital length of stay (–3.6 days [IQR, –4.0 to –3.4 days] per 10% increase; P < .001). Higher weaning adherence was associated with shorter median sedative infusion duration for all sedative classes combined (–1.1 days [IQR, –1.2 to –1.0 days] per 10% increase in adherence; P < .001) and lower median cumulative exposure to opioids (–3.5 mg/kg [IQR, –3.8 to –3.2 mg/kg]; P < .001), benzodiazepines (–3.4 mg/kg [IQR, –3.8 to –3.0 mg/kg]; P < .001), and α2 agonists (–27.7 µg/kg [IQR, –30.2 to –25.3 µg/kg]; P < .001). Conclusions and Relevance: In this multicenter cohort, adherence to sedative weaning opportunities was low. Higher weaning adherence was independently associated with shorter ICU and hospital lengths of stay and reduced sedative exposure. Improving adherence to sedative weaning opportunities may represent a modifiable target for reducing length of stay and sedative exposure.
- 3 August 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (8) , e2629399
Adherence to Sedative Weaning Opportunities and Length of Stay for Critically Ill Children
Importance: Prolonged sedative exposure in pediatric intensive care units (ICUs) is associated with adverse outcomes including delirium, withdrawal, and neurodevelopmental impairment. Clinical guidelines recommend timely weaning, but adherence to weaning opportunities and its association with clinical outcomes is unknown. Objectives: To evaluate adherence to sedative weaning opportunities and examine the association between weaning adherence and clinical outcomes among pediatric ICU patients. Design, Setting, and Participants: This multicenter cohort study included ICU patients at 4 pediatric academic medical centers admitted between January 1, 2011, and December 31, 2024, with greater than 48 hours of cumulative sedative infusion exposure. Data extraction and analyses were performed between February and November 2025. Neonatal ICU stays were excluded. Exposure: Weaning adherence, defined as the percentage of identified opportunities to wean from sedation that resulted in weaning actions (dose decreases or discontinuations), calculated at the ICU encounter level. An opportunity was defined as 0 or 1 as-needed doses of any sedative in a 12-hour period. Main Outcomes and Measures: The primary outcomes were ICU and hospital length of stay. Secondary outcomes included infusion duration and cumulative sedative dose of each drug class. Multivariable linear regression models adjusted for center, age, and sex examined associations between weaning adherence and outcomes. Results: The cohort included 15 747 ICU encounters from 12 737 patients (median age, 1.1 years [IQR, 0.2-6.5 years]; 56% of encounters among male patients). Median ICU length of stay was 13 days (IQR, 7-25 days) and median hospital length of stay was 26 days (IQR, 14-55 days). Among a median of 30 (IQR, 13-68) opportunities to wean per ICU encounter, overall adherence to weaning opportunities was 28% (IQR, 14%-49%), while missed weaning opportunities were common (median, 72%; IQR 51%-86%). Higher weaning adherence was associated with shorter median ICU length of stay (–2.3 days [IQR, –2.4 to –2.2 days] per 10% increase; P < .001) and shorter median total hospital length of stay (–3.6 days [IQR, –4.0 to –3.4 days] per 10% increase; P < .001). Higher weaning adherence was associated with shorter median sedative infusion duration for all sedative classes combined (–1.1 days [IQR, –1.2 to –1.0 days] per 10% increase in adherence; P < .001) and lower median cumulative exposure to opioids (–3.5 mg/kg [IQR, –3.8 to –3.2 mg/kg]; P < .001), benzodiazepines (–3.4 mg/kg [IQR, –3.8 to –3.0 mg/kg]; P < .001), and α2 agonists (–27.7 µg/kg [IQR, –30.2 to –25.3 µg/kg]; P < .001). Conclusions and Relevance: In this multicenter cohort, adherence to sedative weaning opportunities was low. Higher weaning adherence was independently associated with shorter ICU and hospital lengths of stay and reduced sedative exposure. Improving adherence to sedative weaning opportunities may represent a modifiable target for reducing length of stay and sedative exposure.
- 27 May 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (4) , 406-419.e9
Social Determinants of Health And End-Of-Life Circumstances in A Quaternary Children’s Hospital
- 27 May 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (4) , 406-419.e9
Social Determinants of Health And End-Of-Life Circumstances in A Quaternary Children’s Hospital
- Open Access
- 28 April 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Respiratory-physiology modeling of therapeutic hydrogen inhalation: defining the fraction of inspired hydrogen (FiH2) and flow-rate requirements
Molecular hydrogen (H2 gas) has emerged as a promising therapeutic agent with reported benefits across oxidative stress, inflammation, cardiovascular, and
- 28 April 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessRespiratory-physiology modeling of therapeutic hydrogen inhalation: defining the fraction of inspired hydrogen (FiH2) and flow-rate requirements
Molecular hydrogen (H2 gas) has emerged as a promising therapeutic agent with reported benefits across oxidative stress, inflammation, cardiovascular, and
- 1 April 2026
- Published by Wolters Kluwer Health in Dimensions of Critical Care Nursing
- Vol. 45 (3) , 130-140
Variables Associated With Central Venous Catheter Occlusions in 2 Pediatric ICUs With Differing Maintenance Protocols
Background: There is a lack of standardization in the maintenance of central venous catheters (CVCs) within the critically ill infant population, and CVCs have risks, including occlusions. Objectives: The purpose of this retrospective research study was to compare outcomes for infants aged 37 weeks postmenstrual age (PMA) to 6 months with CVCs managed in 2 intensive care units (ICUs) with 2 different maintenance protocols. Methods: Infants with postmenstrual ages (PMA) ranging from 37 weeks to 6 months who had CVCs sized 1.1 to 3 Fr, inserted between April 2017 and December 2021, were included. Data were extracted manually and electronically. Descriptive and regression analyses were conducted. Results: There were a total of 717 subjects and 878 CVCs in the sample. Infants in ICU 1 were slightly older (median age 18 vs. 7 d), weighed less (median 2.8 vs. 3.5 kg), and had fewer CVC line days (median 15 vs. 20 d). There were 135 occlusions (15.4%), with a 10.8% occlusion rate in ICU 1 and a 33.1% occlusion rate in ICU 2. Unit location (0.024), CVC line days (P <.20) and were included in the multivariate model. CVC line days were found to be a risk factor of occlusion (OR=1.08, 95% CI=[1.04, 1.12], P <.001) after controlling for ethnicity and variables univariately associated with occlusion. Discussion: As CVCs are left in place, the likelihood of experiencing an occlusion increases. These results support prior studies that show CVCs often can fail before completion of intended therapy and underscore the need for maintenance protocols that reduce occlusion rates.
- 1 April 2026
- Published by Wolters Kluwer Health in Dimensions of Critical Care Nursing
- Vol. 45 (3) , 130-140
Variables Associated With Central Venous Catheter Occlusions in 2 Pediatric ICUs With Differing Maintenance Protocols
Background: There is a lack of standardization in the maintenance of central venous catheters (CVCs) within the critically ill infant population, and CVCs have risks, including occlusions. Objectives: The purpose of this retrospective research study was to compare outcomes for infants aged 37 weeks postmenstrual age (PMA) to 6 months with CVCs managed in 2 intensive care units (ICUs) with 2 different maintenance protocols. Methods: Infants with postmenstrual ages (PMA) ranging from 37 weeks to 6 months who had CVCs sized 1.1 to 3 Fr, inserted between April 2017 and December 2021, were included. Data were extracted manually and electronically. Descriptive and regression analyses were conducted. Results: There were a total of 717 subjects and 878 CVCs in the sample. Infants in ICU 1 were slightly older (median age 18 vs. 7 d), weighed less (median 2.8 vs. 3.5 kg), and had fewer CVC line days (median 15 vs. 20 d). There were 135 occlusions (15.4%), with a 10.8% occlusion rate in ICU 1 and a 33.1% occlusion rate in ICU 2. Unit location (0.024), CVC line days (P <.20) and were included in the multivariate model. CVC line days were found to be a risk factor of occlusion (OR=1.08, 95% CI=[1.04, 1.12], P <.001) after controlling for ethnicity and variables univariately associated with occlusion. Discussion: As CVCs are left in place, the likelihood of experiencing an occlusion increases. These results support prior studies that show CVCs often can fail before completion of intended therapy and underscore the need for maintenance protocols that reduce occlusion rates.
- Open Access
- 7 November 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-12
Hydrogen’s Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation (Hydrogen-FAST): study protocol for a trial of inhaled hydrogen gas as an adjunctive therapy in refractory cardiac arrest
Extracorporeal cardiopulmonary resuscitation (ECPR) improves survival for patients experiencing refractory cardiac arrest but is often associated with severe ischemia-reperfusion injury (IRI). Hydrogen gas (H2) has demonstrated promising preclinical efficacy in reducing IRI. The Hydrogen-FAST trial investigates the feasibility and safety of inhaled hydrogen gas as an adjunctive therapy during ECPR in patients with congenital heart disease (CHD). This phase 1 multicenter randomized controlled trial enrolls patients of any age undergoing ECPR due to refractory cardiac arrest associated with underlying cardiac morbidity. Due to the emergent nature of ECPR events, the trial leverages an Exception from Informed Consent enrollment process. Fifty-three participants will be randomized to standard care or standard care plus inhaled 2% H2 gas delivered continuously for 72 h via mechanical ventilator and extracorporeal membrane oxygenation (ECMO) circuit. Primary endpoints include feasibility, measured as the percentage of the first 72 h post-arrest in which hydrogen is successfully administered, with feasibility defined as a mean percentage of ≥90%, and safety, evaluated through incidence rates of treatment-related serious adverse events (SAEs). Secondary endpoints examine clinical outcomes including survival to discharge, ICU length of stay, functional status at 6 months, neurologic function, and markers of ischemic injury. The Hydrogen-FAST trial will provide essential data on the feasibility and safety of H2 administration during ECPR, informing larger efficacy studies and potential broader clinical use in critical care settings. ClinicalTrials.gov NCT05574296. Registered on October 6, 2022. https://clinicaltrials.gov/study/NCT05574296 .
- 7 November 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-12
Open AccessHydrogen’s Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation (Hydrogen-FAST): study protocol for a trial of inhaled hydrogen gas as an adjunctive therapy in refractory cardiac arrest
Extracorporeal cardiopulmonary resuscitation (ECPR) improves survival for patients experiencing refractory cardiac arrest but is often associated with severe ischemia-reperfusion injury (IRI). Hydrogen gas (H2) has demonstrated promising preclinical efficacy in reducing IRI. The Hydrogen-FAST trial investigates the feasibility and safety of inhaled hydrogen gas as an adjunctive therapy during ECPR in patients with congenital heart disease (CHD). This phase 1 multicenter randomized controlled trial enrolls patients of any age undergoing ECPR due to refractory cardiac arrest associated with underlying cardiac morbidity. Due to the emergent nature of ECPR events, the trial leverages an Exception from Informed Consent enrollment process. Fifty-three participants will be randomized to standard care or standard care plus inhaled 2% H2 gas delivered continuously for 72 h via mechanical ventilator and extracorporeal membrane oxygenation (ECMO) circuit. Primary endpoints include feasibility, measured as the percentage of the first 72 h post-arrest in which hydrogen is successfully administered, with feasibility defined as a mean percentage of ≥90%, and safety, evaluated through incidence rates of treatment-related serious adverse events (SAEs). Secondary endpoints examine clinical outcomes including survival to discharge, ICU length of stay, functional status at 6 months, neurologic function, and markers of ischemic injury. The Hydrogen-FAST trial will provide essential data on the feasibility and safety of H2 administration during ECPR, informing larger efficacy studies and potential broader clinical use in critical care settings. ClinicalTrials.gov NCT05574296. Registered on October 6, 2022. https://clinicaltrials.gov/study/NCT05574296 .
- Open Access
- 15 October 2025
- Published by Elsevier in Ultrasonics Sonochemistry
- Vol. 122, 107612
Rapidly dissolving polymeric microbubbles promote supersaturation and in-situ formation of acoustic nanobubbles capable of dynamic pressure sensing
- 15 October 2025
- Published by Elsevier in Ultrasonics Sonochemistry
- Vol. 122, 107612
Open AccessRapidly dissolving polymeric microbubbles promote supersaturation and in-situ formation of acoustic nanobubbles capable of dynamic pressure sensing
- Open Access
- 2 September 2025
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 8 (5)
Automated phenotyping of congenital heart disease for dynamic patient aggregation and outcome reporting
Objectives: Accurate characterization of patients with congenital heart disease is fundamental to research, outcomes reporting, quality improvement, and clinical decision-making. Here we present an approach to computing the anatomy of patients with congenital heart disease based on the whole of their diagnostic and surgical codes. Materials and Methods: All diagnostic and procedure codes for patients cared for between 1981 and 2020 at Boston Children’s Hospital were extracted from a database containing diagnostic codes from echocardiograms, and procedural codes from surgical and catheterization procedures. The pipeline sequentially (1) mapped each of the 7500 native codes to algorithm codes; (2) computed the parent anatomy for each study using a pre-defined hierarchy; (3) computed the parent anatomy for the patient, based on highest ranking parent anatomy; and (4) computed the subcategories and mandatory co-variate findings for each patient. Thereafter, diagnostic accuracy of 500 unseen patients was adjudicated against clinical documentation by clinical experts. Results: A total of 514 541 echocardiograms on 161 735 patients were available for this study. Phenotypes of congenital cardiac diseases were assigned in 84 285 patients (52%), and the remainder were computed to have normal anatomy. Clinicians agreed with algorithm assignments in 96.4% (482 of 500 patients), with disagreements most often representing definitional differences. An interactive dashboard enabled by the output of this algorithm is presented. Conclusions: The computation of detailed congenital heart defect phenotypes from raw diagnostic and procedure codes is possible with a high degree of accuracy and efficiency. This framework may enable tools to support interactive outcomes reporting and clinical decision support.
- 2 September 2025
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 8 (5)
Open AccessAutomated phenotyping of congenital heart disease for dynamic patient aggregation and outcome reporting
Objectives: Accurate characterization of patients with congenital heart disease is fundamental to research, outcomes reporting, quality improvement, and clinical decision-making. Here we present an approach to computing the anatomy of patients with congenital heart disease based on the whole of their diagnostic and surgical codes. Materials and Methods: All diagnostic and procedure codes for patients cared for between 1981 and 2020 at Boston Children’s Hospital were extracted from a database containing diagnostic codes from echocardiograms, and procedural codes from surgical and catheterization procedures. The pipeline sequentially (1) mapped each of the 7500 native codes to algorithm codes; (2) computed the parent anatomy for each study using a pre-defined hierarchy; (3) computed the parent anatomy for the patient, based on highest ranking parent anatomy; and (4) computed the subcategories and mandatory co-variate findings for each patient. Thereafter, diagnostic accuracy of 500 unseen patients was adjudicated against clinical documentation by clinical experts. Results: A total of 514 541 echocardiograms on 161 735 patients were available for this study. Phenotypes of congenital cardiac diseases were assigned in 84 285 patients (52%), and the remainder were computed to have normal anatomy. Clinicians agreed with algorithm assignments in 96.4% (482 of 500 patients), with disagreements most often representing definitional differences. An interactive dashboard enabled by the output of this algorithm is presented. Conclusions: The computation of detailed congenital heart defect phenotypes from raw diagnostic and procedure codes is possible with a high degree of accuracy and efficiency. This framework may enable tools to support interactive outcomes reporting and clinical decision support.
- 2 April 2025
- Published by SAGE Publications in Respiratory Care
- Vol. 70 (4) , 377-383
Performance of Unmodified Mechanical Ventilators With 2% Hydrogen Gas Mixtures
Background: Molecular hydrogen (H 2 ) is a breathable gas that has been shown to have anti-oxidative, anti-inflammatory, and anti-apoptotic properties that may positively impact ischemia-reperfusion injury. The provision of 2% H 2 through unmodified mechanical ventilators may facilitate the clinical translation of H 2 as a therapeutic in critical illness. The effect of 2% H 2 on ventilator performance is unknown. Methods: Unmodified Maquet Servo-i, Maquet Servo-u, Dräger Evita Infinity V500, and Dräger Evita Babylog VN500 ventilators from clinical stock were tested in an experimental closed system using certified, premixed air and O 2 containing 2% H 2 gas. Wall air and O 2 supply were used as control. Ventilator settings were varied across the spectrum of neonatal to adult settings. End points included (1) difference between set and delivered tidal volume (V T ) (Douglas method), (2) difference between set versus delivered O 2 concentration, (3) delivered H 2 concentration (gas chromatography), and (4) ventilator pre-use check malfunction. Correlation between set and measured end points were quantified by linear regression analysis and bias by Bland-Altman analysis. Results: During H 2 administration, the average bias in measured versus set V T was within ± 10% for all ventilators except for the Babylog VN500, which exhibited an average bias of −89.2% (95% CI −107.0 to −71.3). The average bias in measured F IO 2 was within ± 10% of set for all ventilators. Except for the Babylog VN500, all ventilators passed the pre-use check. Conclusions: Unmodified Servo-i, Servo-u, and Evita V500 ventilators deliver 2% H 2 mixtures with acceptable accuracy in V T and F IO 2 . The Babylog VN500, which uses hot-wire anometry and a higher set operating temperature, exhibits unacceptably inaccurate delivery of V T with H 2 mixtures.
- 2 April 2025
- Published by SAGE Publications in Respiratory Care
- Vol. 70 (4) , 377-383
Performance of Unmodified Mechanical Ventilators With 2% Hydrogen Gas Mixtures
Background: Molecular hydrogen (H 2 ) is a breathable gas that has been shown to have anti-oxidative, anti-inflammatory, and anti-apoptotic properties that may positively impact ischemia-reperfusion injury. The provision of 2% H 2 through unmodified mechanical ventilators may facilitate the clinical translation of H 2 as a therapeutic in critical illness. The effect of 2% H 2 on ventilator performance is unknown. Methods: Unmodified Maquet Servo-i, Maquet Servo-u, Dräger Evita Infinity V500, and Dräger Evita Babylog VN500 ventilators from clinical stock were tested in an experimental closed system using certified, premixed air and O 2 containing 2% H 2 gas. Wall air and O 2 supply were used as control. Ventilator settings were varied across the spectrum of neonatal to adult settings. End points included (1) difference between set and delivered tidal volume (V T ) (Douglas method), (2) difference between set versus delivered O 2 concentration, (3) delivered H 2 concentration (gas chromatography), and (4) ventilator pre-use check malfunction. Correlation between set and measured end points were quantified by linear regression analysis and bias by Bland-Altman analysis. Results: During H 2 administration, the average bias in measured versus set V T was within ± 10% for all ventilators except for the Babylog VN500, which exhibited an average bias of −89.2% (95% CI −107.0 to −71.3). The average bias in measured F IO 2 was within ± 10% of set for all ventilators. Except for the Babylog VN500, all ventilators passed the pre-use check. Conclusions: Unmodified Servo-i, Servo-u, and Evita V500 ventilators deliver 2% H 2 mixtures with acceptable accuracy in V T and F IO 2 . The Babylog VN500, which uses hot-wire anometry and a higher set operating temperature, exhibits unacceptably inaccurate delivery of V T with H 2 mixtures.